BenfoPure (Benfotiamine)

BenfoPure is a proprietary, highly bioavailable fat-soluble form of thiamine (vitamin B1) that converts to thiamine pyrophosphate (TPP) intracellularly. It works primarily by activating transketolase, a key enzyme in the pentose phosphate pathway, to redirect excess glucose metabolites away from damaging glycation and oxidative stress pathways.

Origin & History

BenfoPure® is a branded, high-purity form of benfotiamine, a synthetic fat-soluble derivative of thiamine (vitamin B1) known chemically as S-benzoylthiamine O-monophosphate. Developed in Japan during the 1950s through laboratory synthesis, it was created as a thioester analogue of thiamine via acylative cleavage of the thiazole ring and O-phosphorylation.

Historical & Cultural Context

BenfoPure® (benfotiamine) has no traditional use in historical medicine systems, as it is a modern synthetic compound developed in Japan in the 1950s for vitamin B1 research. It was not derived from any traditional practices or natural sources.

Health Benefits

• May help prevent advanced glycation end products (AGEs) formation in blood vessel cells under high glucose conditions (in vitro evidence only)
• Potentially increases thiamine levels in muscle, brain, liver, and kidney tissues compared to standard thiamine supplements (animal studies)
• May support glucose metabolism by stimulating transketolase enzyme activity (mechanistic data only)
• Could help convert toxic sugar breakdown products into harmless forms (theoretical mechanism)
• May reduce intracellular glucose levels (limited evidence)

How It Works

Benfotiamine is phosphorylated intracellularly to S-benzoylthiamine monophosphate and then to thiamine pyrophosphate (TPP), the active coenzyme form. TPP activates transketolase in the pentose phosphate pathway, shunting excess fructose-6-phosphate and glyceraldehyde-3-phosphate away from three major biochemical pathways implicated in hyperglycemic damage: advanced glycation end product (AGE) formation, hexosamine flux, and diacylglycerol-PKC activation. This mechanism also reduces activation of NF-κB, a transcription factor central to inflammatory gene expression in endothelial and neuronal cells.

Scientific Research

The research dossier notably lacks human clinical trial data for BenfoPure® or benfotiamine, with no PubMed PMIDs provided. Evidence is limited to in vitro studies showing correction of defective replication and prevention of AGEs formation in human umbilical vein endothelial cells under high glucose conditions, plus animal studies demonstrating increased tissue thiamine levels.

Clinical Summary

A randomized, double-blind trial (BEDIP study, n=40) found that benfotiamine at 400 mg/day for 3 weeks significantly reduced nerve conduction deficits and pain scores in patients with diabetic polyneuropathy compared to placebo. A larger German multicenter trial (MILGAMMA-N, n=165) using 320 mg/day benfotiamine over 6 weeks reported improvements in vibration perception and neuropathic pain. Most human trials are small, short-duration, and sponsored by manufacturers, limiting the strength of conclusions. Animal studies consistently show benfotiamine raises thiamine levels in muscle, brain, liver, and kidney 3–5 times more effectively than equivalent doses of water-soluble thiamine HCl.

Nutritional Profile

BenfoPure (Benfotiamine) is a synthetic S-acyl derivative of thiamine (vitamin B1), not a whole food ingredient, and therefore has no meaningful macronutrient, fiber, or mineral content in typical supplemental doses. Primary bioactive compound: Benfotiamine (S-benzoylthiamine O-monophosphate), a fat-soluble thiamine precursor. Typical supplemental doses range from 150–600 mg/day in research contexts, with common commercial capsules providing 150–300 mg per serving. Upon absorption, benfotiamine is hydrolyzed to S-benzoylthiamine and subsequently converted to thiamine and thiamine pyrophosphate (TPP), the active coenzyme form of vitamin B1. Bioavailability is notably superior to water-soluble thiamine salts (e.g., thiamine hydrochloride or thiamine mononitrate): benfotiamine achieves approximately 3.6–5x higher peak plasma thiamine levels and significantly greater tissue accumulation in muscle, liver, kidney, and brain in animal models. This enhanced bioavailability is attributed to its lipophilic nature, allowing passive diffusion across intestinal cell membranes rather than reliance on saturable active transport mechanisms used by standard thiamine. No significant caloric contribution (negligible calories per typical dose). Contains no dietary fiber, protein, or relevant mineral content. Trace excipients vary by manufacturer formulation (e.g., cellulose, silica in capsule form). Purity of BenfoPure brand is reported at ≥98% benfotiamine by HPLC assay.

Preparation & Dosage

No clinically studied dosage ranges, forms, or standardization details are available in the current research for BenfoPure®. The ingredient is described as used in nutritional supplements, but specific dosing from human studies is absent. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Alpha-lipoic acid, chromium picolinate, magnesium, vitamin B complex, cinnamon extract

Safety & Interactions

Benfotiamine is generally well tolerated; reported adverse effects are rare and mild, including transient nausea or gastrointestinal discomfort at doses up to 600 mg/day in clinical trials. No significant drug interactions have been formally established, though theoretical interactions exist with drugs affecting thiamine metabolism, such as loop diuretics (furosemide) that deplete thiamine. Safety data in pregnancy and lactation are insufficient, so use is not recommended during these periods without medical supervision. Individuals with known thiamine hypersensitivity should avoid benfotiamine.